Quest Diagnostics vs Edwards Lifesciences
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nation's largest clinical lab with 230M tests/year; $9.8B FY2024 revenue; liquid biopsy and genomic oncology testing growth; consumer-direct app strategy; competes with Labcorp.
About
Quest Diagnostics is the nation's leading provider of diagnostic information services, founded in 1967 as MetPath and headquartered in Secaucus, New Jersey, trading on NYSE (DGX). The company processes approximately 230 million clinical laboratory tests annually, serving patients through approximately 2,250 patient service centers, physician offices, hospitals, and health plans across the United States. For FY2024, Quest generated approximately $9.8 billion in total revenues under CEO James Davis, who succeeded Steve Rusckowski in 2022 and has accelerated the company's strategy of expanding consumer access, digital connectivity with ordering physicians, and advanced specialty testing capabilities in oncology, genetics, and infectious disease.
Irvine CA structural heart devices (NYSE: EW) at $5.44B 2024 revenue; 60% TAVR global share, EVOQUE tricuspid +88% in Q4, Critical Care sold to BD for $4.2B, JenaValve acquisition expanding to aortic regurgitation.
About
Edwards Lifesciences Corporation is an Irvine, California-based structural heart disease and hemodynamic monitoring technology company — publicly traded on the New York Stock Exchange (NYSE: EW) as an S&P 500 Healthcare component — designing, developing, and manufacturing devices for heart valve replacement, transcatheter heart valve therapy, and cardiac critical care through approximately 15,800 employees in 100+ countries. In fiscal year 2024, Edwards reported total revenue of $5.44 billion (+8.6% year-over-year), driven by its dominant Transcatheter Aortic Valve Replacement (TAVR) franchise commanding approximately 60% global market share and 70%+ US market share. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated exceptional growth, with Q4 TMTT revenue reaching $105 million (+88% year-over-year), as the EVOQUE tricuspid replacement system gained commercial momentum. In 2024, Edwards executed a major strategic transformation: divesting its Critical Care segment (hemodynamic monitoring) to Becton Dickinson for $4.2 billion — using the proceeds to fund two acquisitions: JenaValve Technology ($1.2B combined, expanding TAVR to high-risk patients with aortic regurgitation) and Endotronix. The company concentrates its entire focus on structural heart disease therapies.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.